FDA approves Novo Nordisk’s Fiasp fast-acting insulin
SILVER SPRING, Md. — The Food and Drug Administration has approved a new fast-acting mealtime insulin from Novo Nordisk. The agency granted approval to Fiasp to treat adults with diabetes.
The drug is a formulation featuring the company’s NovoLog insulin aspart developed with the aim of achieving properties that more closely match the natural physiological insulin mealtime response of someone without diabetes.
“We are very pleased that Fiasp will now also be available to people with diabetes in the United States,” Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said. “The fast action profile of Fiasp allows people with diabetes convenient timing in terms of when to take their insulin in connection with meals to achieve the optimal blood sugar control.”
Mylan launches generic Gleevec
HERTFORDSHIRE, England, and PITTSBURGH — Mylan is expanding its offering of oncology generics with its latest introduction. The company has launched its generic of Gleeven (imatinib mesylate) tablets.
The drug is approved to treat multiple indications, including several blood cancers, the company said. The drug had U.S. sales of approximately $1.7 billion for the 12 months ended July 31, according to QunitilesIMS data. The product will be available in 100- and 400-mg dosage strengths.
The Jean Coutu Group acquired by Metro
MONTREAL — Metro on Monday announced a deal to acquire the Jean Coutu Group for $3.6 billion, creating for a combined food and pharmacy retailer with annual sales of $12.8 billion. As part of the deal, Metro will acquire more than 400 Canadian drug stores and a distribution center.
"Bringing together our two highly-respected and longstanding Quebec brands represents an exciting milestone in the history of the Jean Coutu Group," stated Jean Coutu, chairman of the Jean Coutu Group. "I am confident that this combination will ensure the safeguard of our entrepreneurial vision and corporate values as well as the perennial strength of the brand and will enable us to pursue our growth plan."
"We're honored to become the steward of the iconic Jean Coutu Group brand and we intend to build on this exceptional legacy," added Eric La Fleche, president and CEO Metro. "It is a unique opportunity to bring together each company's expertise to better serve the growing consumer demand for healthier choices, value and convenience," he said. "The Jean Coutu Group's extensive retail network and state-of-the-art distribution center will provide us with increased scale and reach, operational efficencies and enhanced growth potential."
Metro's existing pharmacy distribution and franchising activities will be combined with those of the Jean Coutu Group, which will operate as a stand-alone division of Metro with its own management team led by Francois Coutu.
The combined business will have an overall network of more than 1,300 stores in Canada, with 677 drug stores.